Recent Episodes
Watch recent episodes on
PTV News Review
Scroll Left
Scroll Right
Implicit Bioscience: Accelerating Value Creation in Biotech Firms




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Implicit Bioscience: Accelerating Value Creation in Biotech Firms
Released on: March 01, 2007. © PharmaVentures Ltd
Visitors: You are watching a 5 minute preview.
Get more information and subscribe now
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Fintan Walton talks to Dick Haiduck about his work with Implicit Bioscience, Cytopia and others, and his ‘partner to CEO’ service.
  • Summary
  • Transcript
  • Participants
  • Company
Fintan Walton talks to Dick Haiduck about his work with Implicit Bioscience, Cytopia and others, and his ‘partner to CEO’ service. Dick describes these two different companies - both based in Australia - and their product offerings. The companies are at different stages of development, and therefore have different requirements: Implicit Bioscience is focused on immunology-based drug development, while Cytopia focuses on JAK (Just Another Kinase) inhibitors for cancer treatment. A third company that Dick works with focuses on a point-of-care hydration measurement tool.

Dick, who is CEO of Implicit Bioscience, US Operations, talks about the founding of the firm in 2004; this was based on the principle that quality people are critical to driving success. The company’s business model, which initially involved acquiring assets to a compound previously tested for a different indication, and exploring how new technology can overcome the problems encountered during clinical development, is particularly interesting.

Following a brief discussion of Dick’s industry experience, Fintan asks him about the biotech landscape today, the trend of pharma buying up biotech firms and access to capital for firms. Despite the challenges that the industry faces, Dick assures us that the combination of entrepreneurship and good science in the US are irrepressible, and that these will, inevitably lead to success, even if CEOs have to become increasingly creative.
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Dick Haiduck, BSc, MBA, has extensive experience in the life sciences industry. Prior to his ‘partner to CEO’ work, Dick gained extensive life sciences M&A, and licensing experience as Managing Director, Burrill & Company. Earlier in his career, Dick spent 14 years at Abbott Laboratories, where he held the position of International Company Managing Director, and was at one time responsible for the productivity of Abbott’s US Pharmaceutical Operations.
Implicit Bioscience